SCHEMBL19540973

SCHEMBL19540973

CNC1CCN(C(=O)OC(C)(C)C)CC1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.48
HPGD P15428 1/20 0.47
RECQL P46063 1/20 0.44
PTPN2 P17706 1/20 0.44
PTPN1 P18031 1/20 0.44
PTPN6 P29350 1/20 0.44
ALDH1A1 P00352 3/20 0.43
MAPT P10636 3/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GPR119 Q8TDV5 3/20 0.42
NPC1 O15118 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
USP30 Q70CQ3 1/20 0.41
NR1H2 P55055 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27914509 0.88 EPHX1 (0.48) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL15765934 0.88 EPHX1 (0.48) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL18502917 0.86 EPHX1 (0.47) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL18471329 0.85 USP30 (0.49) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL23931026 0.85 USP30 (0.49) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL23931025 0.85 USP30 (0.49) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL23931084 0.85 USP30 (0.49) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL23931024 0.85 USP30 (0.49) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL2281041 0.85 HPGD (0.48) EPHX1HPGDRECQLPTPN2PTPN1
SCHEMBL12490605 0.85 EPHX1 (0.49) EPHX1HPGDRECQLPTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4081523-B1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2024-12-25 EP disclosed
CN-114901660-B Substituted bicyclic compounds useful as T cell activators 百时美施贵宝公司 2024-10-15 CN disclosed
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-23 US disclosed
WO-2021133750-A1 SUBSTITUTED BICYCLIC PIPERIDINE DERIVATIVES USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-07-01 WO disclosed
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY 2021-06-24 US disclosed
EP-3448850-B1 PIPERIDINYL DERIVATIVES MERCK PATENT GMBH (DE) 2020-11-04 EP disclosed
US-10428024-B2 Piperidinyl derivatives MERCK PATENT GMBH (DE) 2019-10-01 US disclosed
US-20190135753-A1 PIPERIDINYL DERIVATIVES MERCK PATENT GMBH (DE) 2019-05-09 US disclosed
WO-2017186653-A1 PIPERIDINYL DERIVATIVES MERCK PATENT GMBH (DE) 2017-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10428024-B2 Piperidinyl derivatives PDK1, PDK2, PDK3 EPHX1 2058/4885HPGD 124/4885RECQL 431/4885
US-20190135753-A1 PIPERIDINYL DERIVATIVES PDK1, PDK2, PDK3 EPHX1 2058/4885HPGD 124/4885RECQL 431/4885
US-20210188845-A1 SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKA, DGKZ, DGKK EPHX1 3760/4885HPGD 4348/4885RECQL 1308/4885
US-11964973-B2 Substituted bicyclic compounds useful as T cell activators DGKA, DGKZ, DGKK EPHX1 3760/4885HPGD 4348/4885RECQL 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.